Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.
J Med Chem. 2011 Dec 22;54(24):8421-39. doi: 10.1021/jm200906r. Epub 2011 Nov 15.
The systematic structure-activity relationship (SAR) of the muraymycins (MRYs) using an Ugi four-component reaction (U4CR) was investigated. The impact of the lipophilic substituent on antibacterial activity was significant, and the analogues 8 and 9 having a lipophilic side chain exhibited good activity against a range of Gram-positive bacterial pathogens, including MRSA and VRE. Further investigation of compounds 8 and 9 revealed these analogues to be selective inhibitors of the MraY transferase and nontoxic to HepG2 cells. The SAR of the accessory urea-peptide moiety indicated that it could be simplified. Our SAR study of the MRYs suggests a probable mechanism for inhibition of the MraY, where the inner moiety of the urea-dipeptide motif interacts with the carbohydrate recognition domain in the cytoplasmic loop 5. The predicted binding model would provide further direction toward the design of potent MraY inhibitors. This study has set the stage for the generation of novel antibacterial "lead" compounds based on MRYs.
本研究采用 Ugi 四组分反应(U4CR)对 muraymycins(MRYs)进行了系统的结构-活性关系(SAR)研究。脂溶性取代基对其抗菌活性的影响显著,具有脂溶性侧链的类似物 8 和 9 对多种革兰氏阳性菌病原体(包括 MRSA 和 VRE)表现出良好的活性。对化合物 8 和 9 的进一步研究表明,这些类似物是 MraY 转移酶的选择性抑制剂,对 HepG2 细胞无毒。辅助脲-肽部分的 SAR 研究表明,可以对其进行简化。我们对 MRYs 的 SAR 研究表明,其抑制 MraY 的机制可能是,脲二肽模体的内部结构与细胞质环 5 中的碳水化合物识别域相互作用。预测的结合模型将为设计有效的 MraY 抑制剂提供进一步的方向。这项研究为基于 MRYs 的新型抗菌“先导”化合物的生成奠定了基础。